U.S. markets closed

BioAtla, Inc. (BCAB)

NasdaqGM - NasdaqGM Precio en tiempo real. Moneda en USD.
Añadir a la lista de seguimiento
1.5100+0.0950 (+6.71%)
Al cierre: 04:00PM EDT
1.5100 0.00 (0.00%)
Fuera de horario: 04:27PM EDT

BioAtla, Inc.

11085 Torreyana Road
San Diego, CA 92121
United States
858 558 0708
https://www.bioatla.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo65

Descripción

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

Gestión corporativa

La calificación ISS Governance QuickScore de BioAtla, Inc. a partir del 1 de junio de 2024 es 8. Las puntuaciones principales son Auditoría: 5; Junta: 8; Derechos del accionista: 8; Compensación: 8.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.